Evidence map›Paper›PMID 42378300›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

A scalable, dividing cell model for the robust propagation and quantification of human sporadic Creutzfeldt-Jakob disease prions.

Akin Nihat, Parineeta Arora, Christian Schmidt, Melissa L D Rayner, Jacqueline Linehan, Sebastian Brandner, Simon Mead, John Collinge, Parmjit S Jat

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akin Nihat *Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London W1W 7FF, United Kingdom.ORCID 0000-0003-2892-1402
Parineeta Arora *Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London W1W 7FF, United Kingdom.ORCID 0009-0005-5198-8666
Christian SchmidtMedical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London W1W 7FF, United Kingdom.
Melissa L D RaynerDepartment of Pharmacology, University College London School of Pharmacy, London WC1N 1AX, United Kingdom.ORCID 0000-0002-0041-505X
Jacqueline LinehanMedical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London W1W 7FF, United Kingdom.
Sebastian BrandnerDivision of Neuropathology, the National Hospital for Neurology and Neurosurgery, University College National Health Service Foundation Trust, London WC1N 3BG, United Kingdom.
Simon MeadMedical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London W1W 7FF, United Kingdom.ORCID 0000-0002-4326-1468
John CollingeMedical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London W1W 7FF, United Kingdom.ORCID 0000-0003-2220-7566
Parmjit S JatMedical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London W1W 7FF, United Kingdom.ORCID 0000-0002-3354-0594

Funding

UKRI | Medical Research Council (MRC) MR/P019862/1
6 · The paper itself

Abstract

Prion diseases represent a unique biological paradigm with mechanistic parallels to other neurodegenerative conditions like Alzheimer's and Parkinson's diseases. However, the study of human prion pathobiology and the development of effective therapeutics has been severely constrained by the inability to propagate human prions in dividing cells-forcing reliance on costly and slow animal bioassays. Here, we report the generation of EKV cells-a humanized cell model which supports the robust, indefinite propagation of sporadic Creutzfeldt-Jakob disease (sCJD) prions. We demonstrate that these cells replicate bona fide human prion infectivity in culture-cell lysates induce lethal neurodegeneration in humanized mice that is clinically and neuropathologically indistinguishable from inoculation with sCJD-infected brain tissue. We use EKV cells to develop the Human Prion Assay (HPA), which quantifies sCJD infectivity with sensitivity comparable to gold-standard mouse bioassay, while reducing the experimental timeline from years to weeks. Furthermore, we demonstrate that established sCJD infection can be cured by an anti-prion protein antibody, validating the system as a high-throughput platform for drug discovery. This model bridges a critical translational gap, offering a renewable alternative to animal bioassays, a paradigm to dissect the biology of human sCJD prion disease and screen for therapeutic agents.

Indexed as

Creutzfeldt-Jakob SyndromePrionsAnimalsBiological AssayBrainDisease Models, AnimalHumansMiceMice, TransgenicModels, BiologicalPrionsbioassaycell cultureCreutzfeldt–Jakob diseaseinfectivityprion

Identifiers

PMID42378300
PMCPMC13342861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.